The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.
Brian I. Rini
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Bernard J. Escudier
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
M Dror Michaelson
No relevant relationships to disclose
Sylvie Negrier
Honoraria - Pfizer
Research Funding - Pfizer
Martin Eric Gore
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Stephane Oudard
Consultant or Advisory Role - Pfizer
Joseph Clark
No relevant relationships to disclose
Jamal Christo Tarazi
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Brad Rosbrook
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Sinil Kim
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer